

CEO Letter to Adherium Shareholders

Melbourne, Australia – 17 August 2021: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, today provides an update to shareholders from CEO, Rick Legleiter.

Dear Shareholders,

Following my appointment as Adherium's CEO in mid-May I am pleased to provide an update to shareholders as I have taken the reins of the business progress and we move beyond the Respiro takeover process. I am pleased to report my work visa was recently approved by the Australian government and having landed in Sydney I am looking forward to settling back in Melbourne. Before relocating from the USA, I was actively using the time to be leading from the front travelling to business meetings with partners in the US including Monaghan Medical Corporation, the wholly owned subsidiary of Trudell Medical, and HGE Health. In addition, I am developing further partner and customer opportunities in line with our go-to-market strategy.

Now the Respiro takeover has passed I can also report that during the past several months our Board, management and legal team have been diligently working on the Target's Statement and related filings and documentation for you to make a fully informed and up-to-date decision on the Respiro tender. On 16 July 2021, the unsolicited takeover offer by Respiro closed and failed to meet its conditions. At the closing date 0.13% of Adherium shares had accepted the offer, compared to the 50.1% Respiro was seeking.

While the takeover offer was unacceptable from a strategic alignment standpoint and from both the time it consumed and the cost to the company, the legal requirements meant that we had to prepare and issue our Target's Statement and we were restricted from dealing with our share capital. However, you can be assured the diversion did not dissuade our determination of delivering on our strategy for which the \$18 million capital raising was completed in May 2021.

We are pleased that the unsolicited tender from Respiro is concluded and we can now fully focus, without distraction, on the business at hand including the US\$1.6 billion market for severe uncontrolled and difficult to treat Asthma and COPD patients. We have a bright outlook. Our first next generation Hailie sensor (for AstraZeneca's Symbicort inhaler) including psychological measures was submitted to the US Food and Drug Administration

(FDA) for clearance and we have a clear development roadmap for new sensors to expand addressable market coverage. I will be providing additional updates in the coming months on the progress of our development plans, evaluation studies, and eco-system collaboration discussions.

In the meantime, we appreciate the continuing support of all Adherium shareholders.

A handwritten signature in black ink, appearing to read "Rick Legleiter".

Rick Legleiter
Chief Executive Officer
Adherium Limited

This ASX announcement was approved and authorised for release by the Board of Adherium.

About Adherium (ASX: ADR)

Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The Company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organisations. Adherium's Hailie® solution is designed to help patients achieve better adherence and provide visibility to parents and caregivers. It does this by tracking medication use and reminding the user with helpful nudges when it is time to take doses, and by providing access to usage history to better understand patterns in their asthma and COPD.

Adherium has a series of new asthma and COPD sensors in development which, with their existing capabilities, will also enable the capture of physiological measures enabling access to CPT reimbursement for remote patient monitoring in the US.

These tools ultimately enable patients, with their physicians, to more effectively manage their Asthma and COPD and at the same time potentially deliver significant healthcare cost savings to payors and providers.

Learn more at adherium.com

Enquiries: Rick Legleiter
CEO
Adherium Limited
investors@adherium.com